Artrya Elevates Co-Founder to CEO Ahead of U.S. Market Push
Artrya Limited announces a strategic leadership reshuffle with co-founder John Konstantopoulos stepping into the CEO role as the company prepares for its U.S. commercial launch of the Salix® AI-powered platform.
- John Konstantopoulos appointed CEO from 1 July 2025
- Harvey Farrington named Acting CFO to support commercial growth
- Bernie Ridgeway transitions to Executive Chair role
- Leadership changes align with U.S. market commercialisation plans
- Employment terms for key executives disclosed
Leadership Transition Signals New Phase
Artrya Limited, the Australian medical technology company known for its AI-driven Salix® platform targeting coronary artery disease diagnosis, has announced a significant leadership transition effective 1 July 2025. This move comes as the company gears up for its much-anticipated commercial launch in the United States, a critical market for its growth ambitions.
Co-founder John Konstantopoulos, who has been instrumental in developing Artrya’s near real-time, point-of-care technology, will take the helm as Chief Executive Officer. His deep involvement in both the clinical and commercial aspects of the business positions him well to steer the company through this pivotal expansion phase.
Supporting Roles to Drive Commercial Execution
Alongside Konstantopoulos’s appointment, Harvey Farrington, previously the Global Commercial Manager, steps into the role of Acting Chief Financial Officer. Farrington brings a robust background in finance and commercial management, which will be vital as Artrya intensifies its market engagement and operational execution.
Meanwhile, Bernie Ridgeway, formerly Non-Executive Chair, will assume the role of Executive Chair. Ridgeway’s extensive corporate and commercial experience is expected to provide strategic oversight and support as Artrya navigates the complexities of scaling its operations internationally.
Acknowledging Past Leadership and Future Opportunities
The company also expressed gratitude to outgoing CEO Mat Regan for his contributions, particularly in advancing the FDA clearance of the Salix® Coronary Anatomy platform and managing the recent FDA submission for the Coronary Plaque module. These regulatory milestones have laid a solid foundation for Artrya’s commercial objectives.
Konstantopoulos emphasized the exciting opportunities ahead, highlighting the global demand for real-time diagnostic solutions in coronary artery disease. His vision is clear – to leverage the company’s innovative technology and partner network to deliver tangible results for shareholders and the broader healthcare community.
Employment Terms Reflect Commitment
Details disclosed in the announcement reveal Konstantopoulos’s CEO remuneration at $350,000 per annum plus incentives, with a six-month notice period and post-employment restraints to protect company interests. Ridgeway’s Executive Chair role includes a $150,000 annual remuneration on a part-time basis, with eligibility for long-term incentives subject to shareholder approval.
These leadership changes underscore Artrya’s transition from a development-focused entity to a commercially driven enterprise, with a sharpened focus on executing its U.S. market strategy and expanding its global footprint.
Bottom Line?
Artrya’s leadership overhaul sets the stage for a critical commercial push in the U.S., with execution now the key watchpoint.
Questions in the middle?
- How will the new leadership team accelerate Artrya’s U.S. commercial rollout?
- What are the timelines and expectations for FDA approvals of remaining Salix® modules?
- How will these leadership changes impact investor confidence and capital raising efforts?
